Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers reported that asynchronous teledermatology effectively diagnosed and managed non-scarring alopecia in 91.3% of cases within the UPMC network, improving access for underserved populations, with high engagement from Black and Asian patients and significant participation from those living outside Pittsburgh.

In this case study, an 18-year-old woman's triangular alopecic patch diagnosed as temporal triangular alopecia was considered non-progressive and had no impact on her quality of life, so no treatment was initiated.

This review discusses traction alopecia in individuals with Afro-textured hair and emphasizes the importance of education to prevent this condition, but it reports no new clinical results.

This study found that external application of DGD activates the Wnt/β-catenin signaling pathway, promoting hair follicle anagen phase entry, and is a more effective and safer treatment for androgenetic alopecia in mice compared to oral administration.

The authors of this meta-analysis suggest that intralesional injections of methotrexate and vitamin D3 may serve as safe and effective alternatives to triamcinolone acetonide for treating localized alopecia areata in adults, with trichoscopy aiding early detection of treatment effects.

In this case report from Cipto Mangunkusumo Hospital Jakarta, alopecia areata was identified as the most common type of baldness in the facility's skin and genital polyclinics from 2009 to 2011, representing 39.7% of cases.

This article discusses hair follicle testing as an alternative method for drug abuse screening but reports no new research findings.

This study found that deleting the ATR gene in adult mice led to rapid onset of age-related traits such as hair graying and osteoporosis through reduced regenerative capacity.

In this study, patients with alopecia areata were found to have higher high-sensitivity cardiac troponin T levels compared to healthy controls, indicating a potential link between the condition and cardiovascular risk.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This study found that adding low-dose dutasteride to ongoing finasteride treatment significantly improved hair density in a patient with androgenetic alopecia.

This study found that intradermal injections of cultured autologous dermal sheath cup cells for androgenetic alopecia showed hair loss stabilization at 24 months without serious adverse effects and a sustained response in some participants.

This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.

The authors concluded that some patients clinically diagnosed with telogen effluvium may actually have alopecia areata incognita, suggested by the presence of dystrophic hairs and development of alopecia patches.

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.

This study developed and validated a reliable RP-HPLC method for accurately quantifying dutasteride in pharmaceutical formulations and bulk pharmaceuticals using a Shiseido C18 analytical column, demonstrating precision, accuracy, and sensitivity across a concentration range of 10 to 22 ppm.

This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.

This study found that transgender and gender diverse patients on masculinizing hormone therapy had 2.5 times the rate of androgenetic alopecia compared to cisgender women.

This study suggests that low-dose radiotherapy may lead to temporary neurological improvements in some Alzheimer's patients, with 20% showing cognitive improvement at 6 months; it was well-tolerated, though larger trials are needed for confirmation.

This study found that anagen stage protein homogenates and specific epitopes from melanogenesis proteins activated CD8 T cells, suggesting alopecia areata is an anagen-specific disease.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

The device improved hair growth and thickness in men without side effects.

This narrative review discusses the initiation and monitoring of gender-affirming hormone therapy in Australia, noting standard testosterone use for trans men and estradiol with anti-androgens for trans women, emphasizing the importance of monitoring cardiovascular and bone health.

Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.